Michael Schlander

Michael Schlander is a Professor of Health Economics at the University of Heidelberg and Head of the Division of Health Economics at the German Cancer Research Center (DKFZ). His work focuses on the socioeconomic impact of cancer, health technology assessment (HTA), and orphan diseases. He founded the Institute for Innovation & Valuation in Health Care (InnoVal HC) and chairs its activities. His research emphasizes cost-effectiveness analysis, patient-reported outcomes, and policy-relevant evaluations of healthcare interventions.

Research Interests

• Cancer economics and its global burden
• Healthcare resource allocation and HTA methodologies
• Evaluation of orphan medicinal products (OMPs)
• Socioeconomic impact analysis of cancer treatments
• Health policy reforms and pharmaceutical pricing strategies

Recent Contributions

He has led initiatives such as the Heidelberg Health Economics Summer School and contributed to international conferences like ISPOR and the European Society for Medical Oncology (ESMO). His work bridges academic research with practical policy, addressing challenges in cost-effectiveness frameworks and equity in healthcare access. Key areas of focus include:

• Cost-benefit analyses of cancer screening programs
• Comparative HTA outcomes between Germany, France, and England
• Ethical considerations in rare disease treatment evaluations

Labs/Teams

He leads the Division of Health Economics at DKFZ, collaborating with global experts on projects like socioeconomic impact research and CAR T-cell therapy cost optimization. His team also explores postconventional health economics frameworks to address gaps in traditional cost-effectiveness models.